AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions

Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2

Silo Pharma expands license agreement and patent portfolio

Silo enters into commercial evaluation license agreement for next generation liposomes

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis

Novartis Cosentyx receives positive CHMP opinion for use in childhood arthritic conditions

Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU

Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor

It is developing the drug candidate to potentially treat immunological diseases

Global Cord Blood Corp acquires Cellenkos to advance cell therapy market

CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products

Moderna announces expansion in key Asian markets

New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong